6,685 results on '"Urinary Bladder, Overactive"'
Search Results
2. A Prospective Non-interventional Study in Overactive Bladder (OAB) Patients Prescribed Betmiga® as Part of Routine Clinical Practice (BELIEVE)
3. A Study to Evaluate Safety and Efficacy of YM178 in Patients With Overactive Bladder
4. A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron Oral Suspension in Pediatric Subjects From 3 to Less Than 12 Years of Age With Neurogenic Detrusor Overactivity (NDO) or Overactive Bladder (OAB)
5. A Study of YM178 in Patients With Symptomatic Overactive Bladder
6. Study to Test the Efficacy and Safety of YM178 in Subjects With Symptoms of Overactive Bladder (Blossom)
7. A Study on Anticholinergic Use: Attribution of Overactive Bladder (OAB) Medications to the Anticholinergic Burden
8. Diversity in Patients With OAB (DOAB)
9. Effect of Pelvic Floor Down-training on Women With Idiopathic Overactive Bladder
10. Cefar URO - Symptomatic Treatment of Overactive Bladder
11. Efficacy and Safety of VDS+SU in the Treatment of OAB-dry in Children
12. Evaluation of Implantable Tibial Neuromodulation Pivotal Study (TITAN 2)
13. Single Dose Study to Measure Blood Levels and Safety of a Drug for Children With Overactive Bladder
14. Postmarketing Study to Evaluate add-on Therapy With Anticholinergics in Patients With Overactive Bladder (OAB) on Mirabegron.
15. A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of Mirabegron OCAS (Oral Controlled Absorption System) in Pediatric Subjects With Neurogenic Detrusor Overactivity or Overactive Bladder
16. A Clinical Study to Investigate How Solifenacin Fluid is Taken up, How Long it Stays in the Body and How Effective and Safe it is in Treating Children Aged From 6 Months to Less Than 5 Years With Symptoms of Neurogenic Detrusor Overactivity (NDO)
17. A Study to Investigate How Effective and Safe Solifenacin Succinate Suspension is in Treating Children/Adolescents Aged 5 to Less Than 18 Years With Symptoms of Overactive Bladder (OAB) Compared to a Non-active Drug (LION)
18. This Was a Multinational Study Comparing the Efficacy and Safety of Two Medicines , Solifenacin Succinate and Mirabegron Taken Together, or Separately, or a Mock Treatment (Placebo) in Subjects With Symptoms of Overactive Bladder (SYNERGY)
19. Single-dose Study to Assess Pharmacokinetics of Solifenacin Succinate Suspension in Children and Adolescents
20. A Multinational Study Comparing the Long-term Efficacy and Safety of Two Medicines, Solifenacin Succinate and Mirabegron Taken Together, or Separately, in Subjects With Symptoms of Overactive Bladder (SYNERGY II)
21. A Trial Comparing Combination Treatment (Solifenacin Plus Mirabegron) With One Treatment Alone (Solifenacin) (BESIDE)
22. A Study to Evaluate the Efficacy, Safety and Tolerability of Mirabegron and Solifenacin Succinate Alone and in Combination for the Treatment of Overactive Bladder (Symphony)
23. INvestigation of TENS Efficacy Versus Posterior Tibial Nerve Stimulation for Overactive Bladder (INTENSE)
24. Sacral Neuromodulation for Male Overactive Bladder (MOAB)
25. INTIBIA Pivotal Study
26. Treatment Persistence Among Patients With Overactive Bladder: A Retrospective Secondary Data Analysis in Asia Oceania
27. A Prospective, Observational, Multicenter Study of Patients Following Initiation of a New Course of Treatment for Overactive Bladder (OAB) (PERSPECTIVE)
28. A Study to Learn How Effective and Safe the Drug 'Mirabegron' is and How Long it Stays in the Body of Children Aged 6 Months to Less Than 3 Years of Age With Neurogenic Detrusor Overactivity
29. Laser Treatment of Genito-urinary Syndrome in Women
30. Laser Therapy for Treatment of Urogenital Symptoms in Women
31. Development of Novel Cystometrics for Overactive Bladder
32. Pivotal Study of eCoin for Overactive Bladder With Urgency Urinary Incontinence
33. TReating Incontinence for Underlying Mental and Physical Health (TRIUMPH)
34. Darifenacin x Parasacral Transcutaneous Electric Nerve Stimulation for OAB in Patients Infected With Human T-Lymphotropic Virus 1
35. Botulinum Toxin a Vs Anticholinergic Treatment of Neurogenic Overactive Bladder in Patients with Multiple Sclerosis (SEPTOX)
36. Transcutaneous Tibial Nerve Stimulation for Overactive Bladder Syndrome and Associated Gait Changes in Post-menopausal Women (TTNS)
37. Efficacy of Combined Pharmacotherapy Versus Solifenacin with Vaginal Estrogen Cream for Women with Detrusor Overactivity
38. Dose Escalation Study of EG110A, Administered by Intradetrusor Injections to Adults with Neurogenic Detrusor Overactivity-related Incontinence Following Spinal Cord Injury Who Regularly Perform Clean Intermittent Catheterization
39. Prophylactic Analgesia for Bladder Botox Injections
40. Yoga for Treatment of Overactive Bladder in Pediatric Patients
41. PTNS for Female Patients Suffering From Multiple Sclerosis (PTNS-MS)
42. BTL Emsella Chair Versus Sham for the Treatment of Overactive Bladder (EmsellaOAB)
43. Usability Study of the FemPulse System
44. OptiLUTS Part C: the Development of a Symptom Assessment Tool in Sacral Neuromodulation. (OptiLUTS)
45. Behavioral or Solifenacin Therapy for Urinary Symptoms in Parkinson Disease (BOSS PD)
46. Enhancing Pelvic Floor Function With Transcranial Magnetic and Tibial Nerve Stimulation for Neurogenic Bladder in MS
47. Botulinum Neurotoxin Type A (BoNT-A) in Paediatric Non-neurogenic Therapy Resistant Overactive Bladder (OAB)
48. A Study to Evaluate Mirabegron in Pediatric Participants From 5 to Less Than 18 Years of Age With Overactive Bladder (OAB) (Dolphin)
49. Urinary Neurotrophin Levels as Potential Biomarkers for Overactive Bladder: A Case-Control Study (urinary)
50. Vaginal Estradiol vs Oral Beta-3 Agonist for Overactive Bladder Syndrome
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.